Scientific article
Open access

Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals

Published inFrontiers in immunology, vol. 12, 820126
Publication date2022-02-10
First online date2022-02-10

This study aims to assess the immunological response and impact on virological control of the mRNA vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people living with HIV (PLWH). In this single-center observational study, all PLWH were offered vaccination with mRNA1273 or BNT162b2. Both anti-N and anti-S1-receptor binding domain (RBD) antibodies were measured together with HIV-1 RNA levels after the first dose (M0) and then at 1 (M1), 2 (M2) and 6 (M6) months later. A total of 131 individuals (median age: 54 years [IQR: 47.0-60.5]; male: 70.2%; median baseline CD4 T-cell: 602/µl [IQR 445.0-825.5]; median nadir CD4 T-cells 223/µl [IQR 111.0-330.0]) were included. All participants were positive for anti-RBD antibodies at 30 days, 60 days and 6 months after the first dose, with no statistical difference between those with HIV-1 RNA below or >20 copies/ml. HIV-1 RNA data were collected for 128 patients at baseline and 30 days after the first dose; for 124 individuals, 30 days after the second dose; and for 83 patients, 6 months after the first dose. Nineteen (14.8%) of 128 had detectable HIV-1 RNA (>20 copies/ml) at M0, 13/128 (10.2%) at M1 (among which 5 were newly detectable), 15/124 (12.1%) at M2 (among which 5 were newly detectable), and 8/83 (9.6%) at M6. No serious adverse effects were reported. All participants elicited antibodies after two doses of mRNA vaccines, with only a minor impact on HIV-1 RNA levels over a 6-month period.

  • HIV
  • PLWH
  • SARS-CoV-2
  • Serology
  • Vaccination
  • 2019-nCoV Vaccine mRNA-1273 / immunology
  • Adult
  • Aged
  • Antibodies, Viral / blood
  • Antibody Formation
  • BNT162 Vaccine / immunology
  • CD4-Positive T-Lymphocytes / immunology
  • COVID-19 / immunology
  • Coronavirus Nucleocapsid Proteins / immunology
  • Female
  • HIV Infections / immunology
  • HIV-1 / physiology
  • Humans
  • Immunity, Heterologous
  • Male
  • Middle Aged
  • Phosphoproteins / immunology
  • RNA, Viral / analysis
  • SARS-CoV-2 / physiology
  • Spike Glycoprotein, Coronavirus / immunology
  • Vaccination
  • Geneva University Hospitals - Projet de recherche et développement (PRD) [2021-00491]
Citation (ISO format)
PORTILLO, Vera et al. Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals. In: Frontiers in immunology, 2022, vol. 12, p. 820126. doi: 10.3389/fimmu.2021.820126
Main files (1)
Article (Published version)
ISSN of the journal1664-3224

Technical informations

Creation08/25/2022 7:03:00 AM
First validation08/25/2022 7:03:00 AM
Update time03/16/2023 8:57:40 AM
Status update03/16/2023 8:57:40 AM
Last indexation05/06/2024 2:36:36 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack